New post hoc analysis confirms: Airsonett TLA effective for severe asthma exacerbations, improves quality of life and is cost-effective
The Swedish MedTech company Airsonett’s treatment for severe allergic diseases, TLA, has been proven effective for patients with severe exacerbations (asthma flare-ups) and improving the quality of life while being cost-effective. That is the result of a new post hoc analysis of a previous study.
TLA treatment creates a zone of 99.5 percent clean air around the patient's breathing area during night. When the patient is not exposed for allergen and particles, the immune system and airways can rest and the patient gains better resistance to allergens during the day as well.
The potential of TLA in reducing severe asthma exacerbations was addressed in a recent randomized placebo-controlled trial (RCT) in patients with severe asthma (Global Initiative for Asthma (GINA) step 4/5), but the results were inconclusive. The post hoc analysis re-analyzed the RCT with severe exacerbations stratified by the level of baseline asthma symptoms and Quality of Life.
For patients with poor control defined by ACQ7 > 3, the difference in EQ5D-5 L utility scores between TLA and placebo was significant at 9 and 12 months with a cost-effective ICER.
“This post hoc analysis demonstrated an effect of TLA over placebo on severe exacerbations, asthma control and health economics in a subgroup of patients with more symptomatic severe allergic asthma. The results are consistent with the present recommendations for TLA.”
Read the publication here: https://bmcpulmmed.biomedcentral.com/articles/10.1186/s12890-022-02205-6
"We are very pleased with the publication of this post hoc analysis. The results correspond well with our experience from the more than 800 patients that today receive TLA treatment," says Anders Due-Boje, CEO of Airsonett.
About the TLA treatment
The treatment with TLA is given at home with the medical device Airsonett Air4. The technology creates a zone of 99.5 percent clean air, free of allergens and particles, around the patient's breathing area during sleep or rest. When the biological stress decreases during the night, the immune system and airways rest and the patient gains better resistance to allergens during the day as well.
The treatment is clinically proven effective and is currently prescribed by the healthcare system in Sweden to approximately 800 patients with severe allergic diseases. The treatment is included in the national Swedish guidelines for asthma. The company is preparing to launch in other markets in Europe and is developing the next generation of the product, which is expected to be launched in 2023.
For more information:
Anders Due-Boje, CEO, Airsonett AB
Phone: +46 70 526 03 00